{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:46:33Z","timestamp":1787496393149,"version":"build-2736575974"},"reference-count":13,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Rifalazil, a semisynthetic rifamycin, was shown previously to have exceptional potency against\n                    <jats:italic>Chlamydia trachomatis<\/jats:italic>\n                    (MIC of 0.00025 \u03bcg\/ml). We therefore tested 250 additional rifamycin derivatives and identified 12 with activities that are eightfold more potent than that of rifalazil. These compounds also showed exceptional activities against rifampin-resistant strains that carry missense mutations in the\n                    <jats:italic>rpoB<\/jats:italic>\n                    gene. The antimicrobial potency and intracellular penetration of these agents suggest their potential in treatment of chlamydial infections.\n                  <\/jats:p>","DOI":"10.1128\/aac.49.9.3974-3976.2005","type":"journal-article","created":{"date-parts":[[2005,8,26]],"date-time":"2005-08-26T18:07:52Z","timestamp":1125079672000},"page":"3974-3976","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Activities of Rifamycin Derivatives against Wild-Type and\n                    <i>rpoB<\/i>\n                    Mutants of\n                    <i>Chlamydia trachomatis<\/i>"],"prefix":"10.1128","volume":"49","author":[{"given":"Minsheng","family":"Xia","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Suchland","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joli A.","family":"Carswell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Van Duzer","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra K.","family":"Buxton","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Brown","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rothstein","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Stamm","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1571-1573.2002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00286-0"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2316-2318.2003"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3001-3008.2001"},{"key":"e_1_3_2_6_2","first-page":"317","volume":"21","year":"1997","unstructured":"Kuo, C.-C., J. T. Grayston, and T. Hidaka. 1997. A comparison of the in vitro sensitivity of Chlamydia pneumoniae to macrolides and a new benzoxazinorifamycin, KRM-1648. Infect. Dis. Ther.21:317-321.","journal-title":"Infect. Dis. Ther."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/004982598239173","volume":"28","year":"1998","unstructured":"Mae, T., K. Hosoe, T. Yamamoto, T. Hidaka, T. Ohashi, J. M. Kleeman, and P. E. Adams. 1998. Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica28:759-766.","journal-title":"Xenobiotica"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/004982500406408"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1135-1136.2003"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.2.255"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"S562","DOI":"10.1093\/clinids\/5.Supplement_3.S562","volume":"5","year":"1983","unstructured":"Schachter, J. 1983. Rifampin in chlamydial infections. Rev. Infect. Dis.5(Suppl. 3):S562-S564.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.636-642.2003"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1120-1126.2005"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1248\/cpb.41.148","volume":"41","year":"1993","unstructured":"Yamane, T., T. Hashizume, K. Yamashita, E. Konishi, K. Hosoe, T. Hidaka, K. Wattanabe, H. Kawaharada, T. Yamamoto, and F. Kuze. 1993. Synthesis and biological activity of 3\u2032-hyroxy-5\u2032-aminobenzoxazinorifamycin derivatives. Chem. Pharm. Bull.41:148-155.","journal-title":"Chem. Pharm. Bull."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.9.3974-3976.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.9.3974-3976.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T13:56:15Z","timestamp":1645451775000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.9.3974-3976.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1128\/AAC.49.9.3974-3976.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.9.3974-3976.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"2005-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-04-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}